CELYAD SA/ADR (NASDAQ:CYAD) has received a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $47.50.
A number of analysts have commented on the stock. Zacks Investment Research upgraded shares of CELYAD SA/ADR from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research note on Thursday, November 15th. HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of CELYAD SA/ADR in a research note on Monday, November 12th. William Blair restated a “buy” rating on shares of CELYAD SA/ADR in a research note on Monday, November 12th. Finally, Piper Jaffray Companies decreased their price target on shares of CELYAD SA/ADR to $51.00 and set an “overweight” rating for the company in a research note on Monday, November 12th.
Get CELYAD SA/ADR alerts:
CYAD stock traded up $0.18 during midday trading on Monday, reaching $20.99. 2,633 shares of the company’s stock traded hands, compared to its average volume of 4,687. The firm has a market capitalization of $211.36 million, a PE ratio of -5.93 and a beta of 1.86. CELYAD SA/ADR has a 52 week low of $15.36 and a 52 week high of $38.48.
Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC purchased a new position in CELYAD SA/ADR during the 2nd quarter worth $582,000. Wells Fargo & Company MN boosted its holdings in CELYAD SA/ADR by 1,109.0% during the 3rd quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after acquiring an additional 5,545 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in CELYAD SA/ADR by 2.8% during the 3rd quarter. Victory Capital Management Inc. now owns 621,162 shares of the company’s stock worth $16,374,000 after acquiring an additional 17,160 shares during the last quarter. 7.29% of the stock is currently owned by hedge funds and other institutional investors.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Read More: S&P 500 Index